WO2008008455A3 - Method of treating multiple myeloma - Google Patents

Method of treating multiple myeloma Download PDF

Info

Publication number
WO2008008455A3
WO2008008455A3 PCT/US2007/015926 US2007015926W WO2008008455A3 WO 2008008455 A3 WO2008008455 A3 WO 2008008455A3 US 2007015926 W US2007015926 W US 2007015926W WO 2008008455 A3 WO2008008455 A3 WO 2008008455A3
Authority
WO
WIPO (PCT)
Prior art keywords
multiple myeloma
treating multiple
methods
relates
treating
Prior art date
Application number
PCT/US2007/015926
Other languages
French (fr)
Other versions
WO2008008455A2 (en
Inventor
Kelvin P Lee
Lawrence H Boise
Original Assignee
Univ Miami
Kelvin P Lee
Lawrence H Boise
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Miami, Kelvin P Lee, Lawrence H Boise filed Critical Univ Miami
Publication of WO2008008455A2 publication Critical patent/WO2008008455A2/en
Publication of WO2008008455A3 publication Critical patent/WO2008008455A3/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A61K47/6811—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a protein or peptide, e.g. transferrin or bleomycin
    • A61K47/6817—Toxins
    • A61K47/6819—Plant toxins
    • A61K47/6825—Ribosomal inhibitory proteins, i.e. RIP-I or RIP-II, e.g. Pap, gelonin or dianthin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6849—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a receptor, a cell surface antigen or a cell surface determinant
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6891—Pre-targeting systems involving an antibody for targeting specific cells
    • A61K47/6897—Pre-targeting systems with two or three steps using antibody conjugates; Ligand-antiligand therapies
    • A61K47/6898—Pre-targeting systems with two or three steps using antibody conjugates; Ligand-antiligand therapies using avidin- or biotin-conjugated antibodies
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B82—NANOTECHNOLOGY
    • B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/75—Agonist effect on antigen

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Molecular Biology (AREA)
  • Toxicology (AREA)
  • Biophysics (AREA)
  • Nanotechnology (AREA)
  • Organic Chemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Botany (AREA)
  • Medical Informatics (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Cell Biology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

The present invention relates, in general to multiple myeloma and, in particular, to methods of treating multiple myeloma by modulating CD28-mediated regulation of multiple myeloma cell proliferation and survival. The invention also relates to compounds and compositions suitable for use in such methods.
PCT/US2007/015926 2006-07-14 2007-07-13 Method of treating multiple myeloma WO2008008455A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US83067906P 2006-07-14 2006-07-14
US60/830,679 2006-07-14

Publications (2)

Publication Number Publication Date
WO2008008455A2 WO2008008455A2 (en) 2008-01-17
WO2008008455A3 true WO2008008455A3 (en) 2008-04-10

Family

ID=38923906

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2007/015926 WO2008008455A2 (en) 2006-07-14 2007-07-13 Method of treating multiple myeloma

Country Status (1)

Country Link
WO (1) WO2008008455A2 (en)

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040175827A1 (en) * 2001-07-02 2004-09-09 Fowler Daniel H. Methods of generating human cd4+ th2 cells and uses thereof
US20050118173A1 (en) * 2003-09-22 2005-06-02 Xcyte Therapies, Inc. Compositions and methods to accelerate hematologic recovery

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040175827A1 (en) * 2001-07-02 2004-09-09 Fowler Daniel H. Methods of generating human cd4+ th2 cells and uses thereof
US20050118173A1 (en) * 2003-09-22 2005-06-02 Xcyte Therapies, Inc. Compositions and methods to accelerate hematologic recovery

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
KOZBOR ET AL.: "The anti-CD28, 9.3 monocloanal antibody", J. IMMUNOL., vol. 138, 1987, pages 4128 - 4132 *
QIU ET AL.: "CD28 Mab that induces apoptosis in MM Cell lines in vitro", CELL. IMMUNOL., vol. 236, 2005, pages 154 - 160 *

Also Published As

Publication number Publication date
WO2008008455A2 (en) 2008-01-17

Similar Documents

Publication Publication Date Title
HUS2100051I1 (en) Compositions and methods of treating cell proliferation disorders
WO2008128072A3 (en) Axl kinase inhibitors useful for the treatment of cancer or hyperproliferative disorders
WO2005092066A8 (en) Imidazole compounds
WO2010138820A3 (en) N,n-diarylurea compounds and n,n'-diarylthiourea compounds as inhibitors of translation initiation
MY153710A (en) Humanized c-kit antibody
WO2007092622A3 (en) Compositions and methods for treating bone
HK1149950A1 (en) Novel compositions and related methods, coatings, and articles
WO2008027812A3 (en) Imidazopyridine and imidazopyrimidine derivatives
WO2009126786A3 (en) Improved quenching methods for red blood cell pathogen inactivation
TN2011000221A1 (en) Pyrazine compounds as phosphodiesterase 10 inhibitors
MX2009004986A (en) Methods of treating hemolytic anemia.
WO2007075439A3 (en) Compositions and methods for treating obesity and related metabolic disorders
EP2425849A3 (en) Compositions and methods using anti-CS1 antibodies to treat multiple myeloma
UA99936C2 (en) Biaryl substituted azabicyclic alkane derivatives
AU2009319796A8 (en) Substituted octahydrocyclopnta (c) pyrrol-4 -amines as calcium channel blockers
WO2007109279A3 (en) Tetrahydropyridothienopyrimidine compounds and methods of use thereof
MX2010007392A (en) Trpa1 antagonists.
WO2010028338A3 (en) Novel compounds as cannabinoid receptor ligands
WO2010032011A3 (en) Anti-fungal therapy
WO2011017132A3 (en) Mk2 inhibitor compositions and methods to enhance neurite outgrowth, neuroprotection, and nerve regeneration
WO2010005565A3 (en) Method of treating glycogen storage disease
WO2009009034A3 (en) Methods and compositions useful in the treatment of mucositis
WO2012017321A3 (en) Treatment for dyslipidemia
WO2007146813A3 (en) Pyridinone analogs as cell proliferation inhibitors
WO2012006068A3 (en) Compounds for the inhibition of cellular proliferation

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 07810407

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

NENP Non-entry into the national phase

Ref country code: RU

122 Ep: pct application non-entry in european phase

Ref document number: 07810407

Country of ref document: EP

Kind code of ref document: A2